TGFB1 and liver dysplastic nodule: BMP7 admission presents a potential therapy for DN, because in experimental settings this treatment leads to (i) reversed TGF-β -induced epithelial-to-mesenchymal transition (EMT), (ii) inhibited renal fibrosis, and (iii) reversed proteinuria to normal in a dose-dependent manner [18,20,22,23].